Day: December 13, 2024

Rogers Provides Update on Its Acquisition of Bell’s 37.5% Stake in MLSE

Written by Customer Service on December 13, 2024. Posted in Mergers And Acquisitions.

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — Rogers Communications (TSX: RCI.A and RCI.B) (NYSE: RCI) today announced it has received clearance from the Competition Bureau to proceed with the acquisition of Bell’s 37.5% stake in Maple Leaf Sports & Entertainment. Rogers and Bell received a “no-action letter” on December 12, 2024, from the Bureau, indicating that the Commissioner of Competition does not intend to challenge Rogers acquisition of Bell’s interest in MLSE. The deal is subject to league approvals and approval from the CRTC. “This reflects an important step in securing approvals and expanding our ownership of MLSE, one of the most prestigious sports and entertainment organizations in the world,” said Tony Staffieri, President and CEO, Rogers. “As Canada’s leading communications and entertainment company,...

Ingredion Incorporated Declares Quarterly Dividend of $0.80 per Share

Written by Customer Service on December 13, 2024. Posted in Public Companies.

WESTCHESTER, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) — Today, the board of directors of Ingredion Incorporated (NYSE: INGR) declared a quarterly dividend of $0.80 per share on the Company’s common stock. The dividend is payable on Jan. 21, 2025, to stockholders of record at the close of business on Jan. 2, 2025. About the CompanyIngredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in nearly 120 countries. With 2023 annual net sales of approximately $8 billion, the Company turns grains, fruits, vegetables, and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion Idea Labs® innovation centers located around the world and more than 12,000 employees,...

AMREP Reports Second Quarter Fiscal 2025 Results

Written by Customer Service on December 13, 2024. Posted in Earnings Releases And Operating Results.

HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 for the second quarter and first six months of 2025 and $8,854,000 and $19,143,000 for the second quarter and first six months of 2024. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with...

Edesa Biotech Reports Fiscal Year 2024 Results

Written by Customer Service on December 13, 2024. Posted in Public Companies.

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded...

MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round

Written by Customer Service on December 13, 2024. Posted in Public Companies.

Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization. Strategic Investors Further Validation of Technology and Growth Potential. Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel.TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan,...

Outlook Therapeutics® Streamlines Operations

Written by Customer Service on December 13, 2024. Posted in Public Companies.

Full NORSE EIGHT Data Readout Expected January 2025 ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that following an internal strategic review, the management team and Board of Directors have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing its efforts to commercially launch LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) and supporting the resubmission of the...

Parks! America, Inc. Reports Fiscal Year 2024 Financial Results

Written by Customer Service on December 13, 2024. Posted in Public Companies.

Management to host conference call on Monday, December 16, 2024, at 4:30 PM ET PINE MOUNTAIN, Georgia, Dec. 13, 2024 (GLOBE NEWSWIRE) — Parks! America, Inc. (OTCPink: PRKA), today announced its financial results for fiscal year 2024 ended September 29, 2024. The summary information in this press release should not be used as the sole basis for making investment decisions. We encourage shareholders to read our complete Annual Report on Form 10-K, which has been posted on the Company’s website animalsafari.com/investor-relations, for a complete view of the Company and its results. Fiscal Year 2024 Segment Financial Results The Company manages its operations on an individual location basis. Financial information regarding each of the Company’s reportable segments are summarized in the tables below. For the three months...

AleAnna, Inc. Announces Completion of Business Combination between Swiftmerge Acquisition Corp. and AleAnna Energy, LLC

Written by Customer Service on December 13, 2024. Posted in Mergers And Acquisitions.

AleAnna Accelerates Efforts to Improve Italy’s Energy Sustainability and Security with Strategic Business CombinationCombination brings emerging leader in Italian natural gas and renewable natural gas to public markets Shares of AleAnna, Inc. to begin trading on Nasdaq on December 16 under the ticker symbol “ANNA” AleAnna stands on the cusp of a major milestone, with the first phase of natural gas production from the Longanesi Field projected to commence in Q1 2025DALLAS and VANCOUVER, British Columbia and ROME, Dec. 13, 2024 (GLOBE NEWSWIRE) — AleAnna, Inc. (together with its subsidiaries, “AleAnna” or the “Company”), an emerging leader in Italy’s energy landscape, announced the completion of the previously announced business combination (the “Business Combination”) between Swiftmerge Acquisition Corp. (NASDAQ: IVCP) (“Swiftmerge”),...

Nokia Corporation: Repurchase of own shares on 13.12.2024

Written by Customer Service on December 13, 2024. Posted in Public Companies.

Nokia CorporationStock Exchange Release13 December 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 13.12.2024 Espoo, Finland – On 13 December 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 872,093 4.22CEUX – –BATE – –AQEU – –TQEX – –Total 872,093 4.22* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014...

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Written by Customer Service on December 13, 2024. Posted in Mergers And Acquisitions.

Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated...

Day: December 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice